-
Braves rock Dodgers to level series, Brewers win thriller
-
Thailand's Jeeno overcomes late wobble to win Lotte Championship
-
Most Asia stocks rally as 'Goldilocks' jobs data ease rate fears
-
Brazil heads to run-off as Bolsonaro pulls off shock first place finish over Lula
-
Sunken Silk Road city reveals Central Asia's lost history
-
EU, China to hold Beijing talks to avert trade war
-
Three years on, Israeli rescuer cannot escape October 7
-
Bolsonaro edges past Lula as nail-biter Brazil vote goes to a run-off
-
Research into weight-loss drugs tipped for Nobel as award week opens
-
Rubio visits Iceland as US boosts Arctic presence
-
US Supreme Court hears bid to shut the door on climate suits
-
Bolsonaro leads Lula as nail-biter Brazil vote goes to a run-off
-
Chourio walk-off single lifts Brewers over Padres
-
Patriots inflict first Bills defeat as Chiefs keep winning
-
Flavio Bolsonaro leads Lula in near-done Brazil vote count
-
Pacific nations take centre stage at 'pre-COP' climate summit
-
Flavio Bolsonaro leads Lula in partial Brazil poll results
-
Ronaldo can return to Portugal team if he wants: coach Jesus
-
Titan FX Launches Second “Dream Beyond Borders 2.0” Brand Commercial Featuring Keisuke Honda
-
Portugal move into Nations League knockout stage, Germany held
-
Patriots inflict first Bills defeat as Rams surge late
-
Ronaldo-less Portugal beat Norway to reach Nations League quarters
-
Brazil's Indigenous back Lula as El Nino fuels forest fires
-
Bosnian Serb strongman claims election win, thanks Trump and Putin
-
Brazil braces for results of election battle between Lula and Bolsonaro
-
Israel wear black armbands in Ireland tie over Hamas attack
-
Indians protest election chief ahead of top court hearing
-
'I fear it could drag on': anxiety takes hold in Ethiopian city wrested from rebels
-
'Verity' kills, Cruise bombs in N. American movie theaters
-
Brazil's Lula and Flavio Bolsonaro face off in knife-edge election
-
Colts top Commanders in NFL London game
-
UK Green party adopts 'Zionism is racism' policy
-
Hundreds of schools to shut Monday as student protests rock France
-
Rio favela residents vote with little hope
-
Three previous two-time Arc de Triomphe winners
-
Evenepoel puts worlds 'disappointment' to bed with European crown
-
'Champion' Daryz wins second successive Arc in fine style
-
Two-time winning Arc trainer Rouget bows out in emotional farewell
-
Daryz wins second successive Prix de l'Arc de Triomphe
-
Battling Djokovic stuns top seed Zverev at China Open
-
England's seven-goal spree sends message to Euro rivals: Kane
-
Spy chief Clayton, the Trump loyalist tech bosses trust on AI
-
Trump confirms national intelligence chief as new AI czar
-
UK's Glastonbury festival tickets sell out in 45 minutes
-
Up to 500 French schools to be totally or partly closed Monday: minister
-
Two dead in Catalonia due to torrential rains: Spanish officials
-
Sydney Roosters edge Knights in tense NRL grand final
-
Verstappen claims first win of year in chaotic Bahrain GP in Malaysia
-
Sabalenka out of China Open in third round, Medvedev into semis
-
Red Bull's Verstappen wins Bahrain Grand Prix in Malaysia
Moderna rebuked over plan to hike Covid vaccine to $130
Moderna's chief executive on Wednesday defended the US company's plan to quadruple the price of its lifesaving Covid vaccine to as much as $130 per dose as soon as government stockpiles run out.
Democratic Senator Bernie Sanders lashed out at the price hike, denouncing the "unprecedented level of corporate greed" in the pharmaceutical industry. "And that is certainly true with Moderna," Sanders said.
Moderna has so far charged between about $15 and $26 for doses of its vaccine, according to the Kaiser Family Foundation.
The US government subsidized $1.7 billion of Moderna's research at the start of the pandemic and then purchased $10 billion worth of vaccine, Sanders said at a Senate hearing where the company's CEO Stephane Bancel was testifying.
Sanders said Moderna was "thanking the taxpayers of the United States" by more than quadrupling the vaccine's price "at a time when it costs less than $3 to manufacture."
Sanders noted several times at the hearing that Moderna conducted buybacks of its own stock and paid its own executives at its Cambridge, Massachusetts, headquarters handsomely.
Bancel defended Moderna, saying the distribution system will change completely when the US government lifts a state of health emergency, perhaps as soon as May.
Up until now, Moderna had only one customer, distributed its vaccine to only a few warehouses and did not have to pay for the cost of expired doses.
By switching to a more traditional marketing approach, "we're going to have 10,000 customers" and have to "manage to deliver to 60,000 pharmacies, doctors' offices and hospitals," he added.
Currently distributed in multidose vials, the vaccine will be sold mostly in single-dose vials or directly in prefilled syringes. And Moderna will have to take care of the unsold doses.
The company expects a "90 percent reduction in demand," Bancel said. "We are losing economies of scale. We must assume the wastage risk and cost that the US government used to assume."
Moderna also pledged to set up a program so that the uninsured or underinsured would not have to pay anything.
When pressed by Sanders about the possibility of the company lowering its price for government-run health insurance programs, Bancel said discussions were underway with all customers.
P.Martin--AMWN